Clinical trial
Avatrombopag for Chemotherapy-induced Thrombocytopenia in Solid Tumors: a Prospective Multi-center One-arm Study
NCT05218226 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Avatrombopag for Chemotherapy-induced Thrombocytopenia in Solid Tumors: a Prospective Multi-center One-arm Study
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- February 10, 2022
- Completion date
- December 31, 2025
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
avatrombopag, chemotherapy-induced thrombocytopenia